Related Experiment Video
Updated: Jan 21, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr)
Na Qu1, Xiaobin Wang1, Yiming Meng2
1Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, Shenyang 110042, Liaoning Province, China.
Abstract:
The standard treatments for neoplasia include surgery, chemotherapy, hormone antagonists and radiotherapy, which can prolong survival, but rarely cure the tumors of gynecological cancer patients. OGF - OGFr expression, in various gynecologic cells and tissues, is an intersection point between cell development, neuroendocrine function and immune modulation. It has been identified that OGF and OGFr expression differs between gynecological tumor and normal cells. Further, exogenous or endogenous OGF and OGFr antagonists have been known to have a role in regulating cell viability and apoptosis. Moreover, the expression of proteins in the OGF - OGFr axis modulate differentiation and membrane expression of immune cells, which can enhance the immune response. In vivo and in vitro assays have shown that OGF and OGFr antagonists inhibit mitosis as well as induce apoptosis in gynecologic cancer cells. Although immune augmentation combination therapies can intensify cytotoxic activity, OGF or OGFr antagonists do not increase toxicities associated with dual-immune regulation. In conclusion, the OGF - OGFr axis provides significant strategies for antitumor efficiency in gynecological cancer.
Insights
The OGF-OGFr axis offers novel therapeutic strategies for gynecological cancers. Antagonists targeting this axis inhibit cancer cell growth and induce apoptosis, enhancing immune response without increasing toxicity.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Standard gynecological cancer treatments prolong survival but rarely achieve cures.
- The OGF-OGFr axis is implicated in cell development, neuroendocrine function, and immune modulation.
- Differential expression of OGF and OGFr is observed between normal and gynecological tumor cells.
Purpose of the Study:
- To investigate the therapeutic potential of the OGF-OGFr axis in gynecological cancer.
- To evaluate the effects of OGF and OGFr antagonists on cancer cell viability and apoptosis.
- To assess the impact of the OGF-OGFr axis on immune cell modulation and overall anti-tumor immunity.
Main Methods:
- In vivo and in vitro assays were employed to study the OGF-OGFr axis.
- The effects of OGF and OGFr antagonists on gynecological cancer cells were analyzed.
- Immune cell differentiation and membrane expression modulation were investigated.
Main Results:
- OGF and OGFr antagonists were found to inhibit mitosis and induce apoptosis in gynecological cancer cells.
- The OGF-OGFr axis modulates immune cell differentiation and membrane expression, potentially enhancing immune response.
- Combination therapies involving OGF or OGFr antagonists did not increase toxicities associated with immune regulation.
Conclusions:
- The OGF-OGFr axis presents a promising target for developing novel anti-cancer strategies in gynecological malignancies.
- OGF and OGFr antagonists demonstrate significant anti-tumor efficiency by inhibiting cancer cell proliferation and promoting apoptosis.
- Targeting the OGF-OGFr axis offers a potential approach to enhance anti-tumor immunity in gynecological cancer patients.
More Related Videos
Related Concept Videos
Opioid Receptors: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity

